These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8748929)

  • 1. Striatal dopamine depletion, tremors, and hypokinesia following the intracranial injection of S-adenosylmethionine: a possible role of hypermethylation in parkinsonism.
    Charlton CG; Crowell B
    Mol Chem Neuropathol; 1995 Dec; 26(3):269-84. PubMed ID: 8748929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substantia nigra degeneration and tyrosine hydroxylase depletion caused by excess S-adenosylmethionine in the rat brain. Support for an excess methylation hypothesis for parkinsonism.
    Charlton CG; Mack J
    Mol Neurobiol; 1994; 9(1-3):149-61. PubMed ID: 7888091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of L-dopa.
    Charlton CG; Crowell B
    Pharmacol Biochem Behav; 1992 Oct; 43(2):423-31. PubMed ID: 1359575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysophosphatidylcholine decreases locomotor activities and dopamine turnover rate in rats.
    Lee ES; Soliman KF; Charlton CG
    Neurotoxicology; 2005 Jan; 26(1):27-38. PubMed ID: 15527871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depletion of nigrostriatal and forebrain tyrosine hydroxylase by S-adenosylmethionine: a model that may explain the occurrence of depression in Parkinson's disease.
    Charlton CG
    Life Sci; 1997; 61(5):495-502. PubMed ID: 9247319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of L-dopa treatment on methylation in mouse brain: implications for the side effects of L-dopa.
    Liu XX; Wilson K; Charlton CG
    Life Sci; 2000; 66(23):2277-88. PubMed ID: 10855949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
    González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
    Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake.
    Chotibut T; Apple DM; Jefferis R; Salvatore MF
    PLoS One; 2012; 7(12):e52322. PubMed ID: 23300642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-adenosyl-L-methionine decreases motor activity in the rat: similarity to Parkinson's disease-like symptoms.
    Crowell BG; Benson R; Shockley D; Charlton CG
    Behav Neural Biol; 1993 May; 59(3):186-93. PubMed ID: 8503824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of homocysteine on the dopaminergic system and behavior in rodents.
    Lee ES; Chen H; Soliman KF; Charlton CG
    Neurotoxicology; 2005 Jun; 26(3):361-71. PubMed ID: 15935208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Rogers JT; Devoto P; Björklund A; Carta M
    Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
    El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
    Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism.
    Collier TJ; Dung Ling Z; Carvey PM; Fletcher-Turner A; Yurek DM; Sladek JR; Kordower JH
    Exp Neurol; 2005 Feb; 191 Suppl 1():S60-7. PubMed ID: 15629762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase.
    Zhao WQ; Latinwo L; Liu XX; Lee ES; Lamango N; Charlton CG
    Exp Neurol; 2001 Sep; 171(1):127-38. PubMed ID: 11520127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
    Alam M; Schmidt WJ
    Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron deficiency alters dopamine uptake and response to L-DOPA injection in Sprague-Dawley rats.
    Bianco LE; Wiesinger J; Earley CJ; Jones BC; Beard JL
    J Neurochem; 2008 Jul; 106(1):205-15. PubMed ID: 18363828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of S-adenosylmethionine-induced tremors: a possible tremor model for Parkinson's disease.
    Lamango NS; Nesby RA; Charlton CG
    Pharmacol Biochem Behav; 2000 Mar; 65(3):523-9. PubMed ID: 10683494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
    Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic effects of dopamine replacement therapy and its psychiatric side effects are mediated by pineal function.
    Willis GL
    Behav Brain Res; 2005 May; 160(1):148-60. PubMed ID: 15836910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.